

# Memo

To: User of Circular of Information

From: Christine Driscoll, Director, Regulatory Affairs and Sarai Paradiso,  
Executive Director, Core Operations

Date: March 17, 2021

Re: Circular of Information Update

---

In accordance with Food and Drug Administration (FDA) Guidance for Industry: FDA Guidance Document, *Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion*, September 2019, New York Blood Center is providing an update to the platelet language.

The following statement is being provided for platelets intended for transfusion and is to be considered part of the Circular of Information.

To control the risk of bacterial contamination in platelets, NYBC uses either 1) pathogen reduction technology, or 2) the single-step, large volume, delayed sampling (LVDS) no sooner than 48-hour strategy for 7-day platelets using BacT/Alert with both aerobic and anaerobic cultures.